Middle aged woman dressed in pink showing strength and smiling in a park. Fight against breast cancer.
getty
A new targeted cancer drug may offer a better first treatment option for one of the most aggressive forms of breast cancer. In a large international clinical trial, patients receiving the drug lived longer and went nearly twice as long before their cancer worsened compared with those receiving standard chemotherapy. The treatment also shrank tumors more often and produced longer-lasting responses.
Triple-negative breast cancer accounts for roughly 10% to 20% of breast cancer cases. Unlike many other breast cancers, it lacks the common targets that make hormone therapies and other precision medicines effective. The disease often spreads quickly, returns early and can be especially difficult to treat once it reaches other parts of the body.
For many patients, chemotherapy remains the main treatment option. Immune-based therapies have improved outcomes for some people, but most patients with advanced triple-negative breast cancer are not candidates for those drugs. As a result, there has been growing interest in treatments that can deliver powerful cancer medicines more precisely while avoiding some of the limitations of traditional chemotherapy.
The new treatment belongs to a growing class of medicines called antibody-drug conjugates. These therapies combine a targeting antibody with a chemotherapy drug.
The antibody acts like a delivery address. It recognizes a protein found in high amounts on many breast cancer cells and attaches to it. Once attached, the cancer cell pulls the drug inside and releases the chemotherapy directly where it is needed.
Traditional chemotherapy travels throughout the body and affects both cancerous and healthy cells. Antibody-drug conjugates take a more focused approach. By concentrating treatment inside tumor cells, they can deliver highly potent chemotherapy while reducing unnecessary exposure elsewhere.
This strategy has already transformed treatment for several cancers, including certain forms of breast cancer. The new trial suggests the approach may also improve outcomes when used as an initial treatment for advanced triple-negative breast cancer.
Triple-negative breast cancer is often more aggressive than other forms of the disease. It tends to spread earlier and is more likely to return after treatment.
The challenge becomes even greater after the cancer has spread beyond the breast. Many patients face limited treatment choices, and responses to chemotherapy are often short-lived.
Nearly 70% of patients with advanced triple-negative breast cancer are not candidates for immune-based treatments. For these individuals, chemotherapy remains the standard first option despite modest response rates and limited durability.
A treatment capable of controlling the disease for longer without substantially increasing serious side effects could therefore fill an important gap.
More than 640 patients with advanced triple-negative breast cancer participated in the trial. None were considered candidates for immune-based therapy.
Patients receiving the targeted drug went an average of almost 11 months before their disease worsened. Those receiving chemotherapy went just under 6 months before progression.
The treatment also improved overall survival. Patients receiving the targeted drug lived an average of almost 2 years compared with about one and a half years for those receiving chemotherapy.
Tumor shrinkage was substantially more common with the targeted therapy. Nearly two-thirds of patients saw their tumors shrink, compared with fewer than one-third of patients receiving chemotherapy. Tumor responses also lasted longer, remaining effective for more than a year on average. A small number of patients even experienced complete disappearance of detectable tumors on imaging scans.
No cancer treatment is free of side effects, and the new drug produced its own set of challenges. The most common problems included mouth sores, nausea and hair loss. Most mouth and eye-related side effects were mild to moderate and could often be managed without stopping treatment.
Serious treatment-related side effects occurred at similar rates in both groups. Importantly, fewer patients stopped treatment because of side effects on the targeted drug than on chemotherapy, and no treatment-related deaths occurred during the trial.
The findings add to growing evidence that guided chemotherapy delivery systems can outperform conventional chemotherapy in aggressive cancers.
The benefit extended beyond tumor shrinkage. Patients lived longer, remained progression-free longer, and were able to stay on treatment for substantially longer periods of time.
The results also reinforce the importance of a certain cell-surface protein, which appears on many triple-negative breast cancer cells and has become an increasingly important target for new cancer medicines.
For patients who cannot receive immune-based therapies, the significance may be straightforward. A disease long defined by limited treatment options may soon have a more effective first-line alternative.
This work is part of a series demonstrating how modern antibody strategies can be developed to enhance immune responses, with potential applications across a wide range of diseases and therapeutic areas.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。